Aziyo Biologics Stock Cash Flow From Operations
| AZYODelisted Stock | USD 2.44 0.00 0.00% |
Aziyo Biologics fundamentals help investors to digest information that contributes to Aziyo Biologics' financial success or failures. It also enables traders to predict the movement of Aziyo Stock. The fundamental analysis module provides a way to measure Aziyo Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aziyo Biologics stock.
Aziyo |
Aziyo Biologics Company Cash Flow From Operations Analysis
Aziyo Biologics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Aziyo Biologics Cash Flow From Operations | (21.43 M) |
Most of Aziyo Biologics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aziyo Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Aziyo Biologics has (21.43 Million) in Cash Flow From Operations. This is 104.07% lower than that of the Health Care Equipment & Supplies sector and 105.87% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 102.21% higher than that of the company.
Aziyo Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aziyo Biologics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aziyo Biologics could also be used in its relative valuation, which is a method of valuing Aziyo Biologics by comparing valuation metrics of similar companies.Aziyo Biologics is currently under evaluation in cash flow from operations category among its peers.
Aziyo Fundamentals
| Return On Equity | -7.75 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.50) % | |||
| Current Valuation | 40.69 M | |||
| Shares Outstanding | 11.92 M | |||
| Shares Owned By Insiders | 2.18 % | |||
| Shares Owned By Institutions | 70.44 % | |||
| Number Of Shares Shorted | 68.02 K | |||
| Price To Book | 13.34 X | |||
| Price To Sales | 1.29 X | |||
| Revenue | 49.19 M | |||
| Gross Profit | 19.22 M | |||
| EBITDA | (22.38 M) | |||
| Net Income | (32.9 M) | |||
| Cash And Equivalents | 16.49 M | |||
| Cash Per Share | 1.21 X | |||
| Total Debt | 34.89 M | |||
| Debt To Equity | 3.50 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (21.43 M) | |||
| Short Ratio | 3.98 X | |||
| Earnings Per Share | (2.18) X | |||
| Target Price | 10.5 | |||
| Number Of Employees | 151 | |||
| Beta | -0.18 | |||
| Market Capitalization | 23.72 M | |||
| Total Asset | 68.84 M | |||
| Retained Earnings | (137.99 M) | |||
| Working Capital | 8.08 M | |||
| Z Score | -2.62 | |||
| Net Asset | 68.84 M |
About Aziyo Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aziyo Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aziyo Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aziyo Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aziyo Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aziyo Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aziyo Biologics will appreciate offsetting losses from the drop in the long position's value.Moving against Aziyo Stock
| 0.69 | EC | Ecopetrol SA ADR | PairCorr |
| 0.59 | SHG | Shinhan Financial | PairCorr |
| 0.58 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.51 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.42 | WF | Woori Financial Group | PairCorr |
The ability to find closely correlated positions to Aziyo Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aziyo Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aziyo Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aziyo Biologics to buy it.
The correlation of Aziyo Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aziyo Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aziyo Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aziyo Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Aziyo Stock
If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |